Physician Views: Will IMPERIAL's favourable Eluvia data spell a sea change in peripheral intervention?

Results from the IMPERIAL study, presented on September 22 at the Transcatheter Cardiovascular Therapeutics (TCT) meeting, demonstrated the superiority of Boston Scientific's Eluvia drug-eluting vascular stent over Cook Medical's Zilver PTX drug-eluting peripheral stent in treating patients with femoropopliteal disease. 

The study findings showed that at 12 months post-procedure, primary patency rate - a measure of the target vessel being unobstructed - in patients treated with Eluvia was 88.5 percent, while in patients treated with Zilver PTX, this was 79.5 percent. This was statisically different for non-inferiority and also for superiority, as a pre-specified post-hoc analysis revealed. Additionally, data demontrated that the Eluvia stent had a target lesion revascularisation (TLR) rate of 4.5 percent, half of the 9.0 percent TLR rate seen with Zilver PTX. Additionally, over 95 percent of patients who received the Eluvia stent were free of major adverse events at one year, compared to 91.0 percent of patients who received the Zilver PTX. 

Zilver PTX became the first drug-eluting stent approved by the FDA for use in the peripheral artery back in 2012. Six years on, it looks like Cook Medical has a serious rival in Boston Scientific, after the company bagged US approval for Eluvia just a couple of days after the IMPERIAL results.

We are snap-polling cardiologists in the US and EU3 (UK, France and Germany) to ascertain whether there is any basis to Boston Scientific's belief that the IMPERIAL results are "practice-changing" and will help accelerate the shift from non-drug approaches – like POBA and bare metal stents to – drug-eluting stents and drug-coated balloon.

Specifically we are asking them…

Q. What percentage of the femoropopliteal disease patient population do you treat with non-drug-based interventions like POBA and bare-metal stents?

Q. What percentage of the femoropopliteal disease patient population do you treat with drug-coated balloons like Medtronic's In.Pact, or with drug-eluting stent, like Cook Medical's Zilver PTX?

Q. Using a five-point scale (1=very unsatisfied/ 5=very satisfied), how satisfied are you with the traditional non-drug/device approaches? 

Q. Using a five-point scale (1=not likely / 5=very likely), how likely are you to switch from POBA/BMS to DCB/DES following the results of the IMPERIAL study?

Q.  If you have had experience with Cook Medical's Zilver PTX, what features about Boston Scientific's Eluvia would convince you to switch DESs?

Results and related analysis will shortly be published for FirstWord Medtech PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions.

Note: FirstWord Physician Views are a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties in major markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

Disclaimer: FirstWord follows market research best practices in conducting its Physician Views polls.  However, Physician Views results should be considered directional and clients should use their market research resources for statistical analysis and conclusions required with very high confidence levels.

Did you like this article?